Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.14
+0.30004.39%
Post-market: 7.140.00000.00%17:52 EDT
Volume:1.94M
Turnover:14.02M
Market Cap:723.67M
PE:-6.97
High:7.55
Open:6.75
Low:6.73
Close:6.84
Loading ...

BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating

MT Newswires Live
·
17 Apr

Day One Biopharmaceuticals price target lowered to $21 from $24 at BofA

TIPRANKS
·
17 Apr

Bank of America Securities Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
17 Apr

UNDER ARMOUR APPOINTS DAWN N. FITZPATRICK, EUGENE D. SMITH, AND ROBERT J. SWEENEY TO ITS BOARD OF DIRECTORS

PR Newswire
·
15 Apr

Day One Biopharm Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Promising Outlook for Day One Biopharmaceuticals: Buy Rating Driven by Ojemda’s Market Potential

TIPRANKS
·
03 Apr

Day One Biopharm Is Maintained at Buy by Goldman Sachs

Dow Jones
·
25 Mar

Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential

TIPRANKS
·
11 Mar

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.
·
11 Mar

Day One Biopharm Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Insider Monkey
·
05 Mar

Day One Biopharma’s Earnings Call Highlights Growth and Challenges

TIPRANKS
·
28 Feb

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Zacks
·
26 Feb

Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial

TIPRANKS
·
26 Feb

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharm Price Target Maintained With a $32.00/Share by Needham

Dow Jones
·
26 Feb

Oppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals Reports Strong 2024 Results

TIPRANKS
·
26 Feb

Promising Growth and Strategic Positioning Justify Buy Rating for Day One Biopharmaceuticals

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb